HC Wainwright Reiterates Buy Rating for Repare Therapeutics (NASDAQ:RPTX)

Repare Therapeutics (NASDAQ:RPTX)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 187.36% from the stock’s previous close.

Separately, Lifesci Capital raised shares of Repare Therapeutics to a “strong-buy” rating in a report on Monday, July 29th.

Repare Therapeutics Price Performance

Shares of RPTX stock opened at $3.48 on Thursday. The business has a fifty day moving average of $3.24 and a 200 day moving average of $3.39. Repare Therapeutics has a 1 year low of $2.71 and a 1 year high of $8.49. The firm has a market capitalization of $147.71 million, a price-to-earnings ratio of -3.16 and a beta of 0.72.

Repare Therapeutics (NASDAQ:RPTX) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.03. The firm had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $4.02 million. Repare Therapeutics had a negative return on equity of 31.11% and a negative net margin of 99.76%. As a group, equities research analysts expect that Repare Therapeutics will post -2.15 earnings per share for the current year.

Institutional Investors Weigh In On Repare Therapeutics

Hedge funds have recently modified their holdings of the company. Vontobel Holding Ltd. increased its stake in shares of Repare Therapeutics by 20.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock valued at $83,000 after purchasing an additional 4,000 shares in the last quarter. XTX Topco Ltd acquired a new stake in Repare Therapeutics in the second quarter valued at approximately $110,000. Exchange Traded Concepts LLC increased its position in shares of Repare Therapeutics by 21.2% in the third quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock valued at $174,000 after buying an additional 8,809 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Repare Therapeutics during the 2nd quarter worth approximately $273,000. Finally, Opaleye Management Inc. purchased a new position in shares of Repare Therapeutics during the 1st quarter valued at approximately $318,000. 85.09% of the stock is owned by hedge funds and other institutional investors.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.